MedTrace Logo

SAD Evaluation of Safety, Tolerability, PK, and PD of MDI-2517 in Healthy Participants

NCT06453824 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-03-14

No results posted yet for this study

Summary

This is a Phase 1 study to test the safety and drug effects of MDI-2517 when given once in healthy volunteers.

Conditions

  • Safety and Tolerability

Interventions

DRUG

MDI-2517

study drug

OTHER

Placebo

matching placebo

Sponsors & Collaborators

  • MDI Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • David Wyatt, MD · Syneos Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-17
Primary Completion
2024-11-11
Completion
2024-11-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06453824 on ClinicalTrials.gov